{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"LY 3484356"},{"type":"CodeName","name":"LY3484356"},{"type":"LexicalVariant","name":"selective estrogen receptor degrader LY3484356"},{"type":"Synonym","name":"SERD LY3484356"},{"type":"CASRegistryName","name":"2408840-26-4"},{"type":"CodeName","name":"LY-3484356"}],"definition":{"html":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","text":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells."},"drugInfoSummaryLink":null,"nciConceptId":"C174042","nciConceptName":"Imlunestrant","termId":802339,"name":"imlunestrant","firstLetter":"i","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"imlunestrant"}],"links":null}